⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9112837 | 0.71 | — | — | |
| SCHEMBL21250591 | 0.67 | — | — | |
| SCHEMBL22433367 | 0.62 | — | — | |
| SCHEMBL74345 | 0.59 | — | — | |
| SCHEMBL1292309 | 0.57 | — | — | |
| Hydrochloric Acid SCHEMBL28179334 | 0.57 | — | — | |
| SCHEMBL8820512 | 0.56 | — | — | |
| SCHEMBL358405 | 0.56 | — | — | |
| SCHEMBL969352 | 0.55 | — | — | |
| SCHEMBL197513 | 0.55 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137765-A1 | TRANSITION-METAL CATALYST COMPOSITIONS AND METHODS FOR SEQUENCING BY SYNTHESIS | ILLUMINA, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024137756-A1 | COMPOUNDS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS | HONGENE BIOTECH CORPORATION (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024097296-A1 | ANTI-VIRAL COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024086111-A1 | ANTI-VIRAL COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| WO-2024072964-A1 | CARBON DIOXIDE SATURATED ELECTROLYTES FOR ENERGY STORAGE DEVICE, AND METHODS THEREOF | TESLA, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024059808-A1 | WEE1 INHIBITORS AND METHODS FOR TREATING CANCER | RECURIUM IP HOLDINGS, LLC (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2024040091-A1 | LIPID-PEGYLATED COMPOUNDS, PREPARATIONS AND USES THEREOF | HONGENE BIOTECH CORPORATION (US) | 2024-02-22 | — | — | WO | disclosed |
| WO-2023205653-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| EP-4251625-A1 | TRICYCLIC COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023178035-A1 | MULTICYCLIC COMPOUNDS | SLAP PHARMACEUTICALS LLC (US) | 2023-09-21 | — | — | WO | disclosed |
| EP-2619216-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | Alios Biopharma, Inc. (US) | 2013-07-31 | — | — | EP | disclosed |
| WO-2013096679-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013096680-A1 | SUBSTITUTED PHOSPHOROTHIOATE NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013082476-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | EMORY UNIVERSITY (US) | 2013-06-06 | — | — | WO | disclosed |
| WO-2013025733-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-02-21 | — | — | WO | disclosed |
| WO-2012088155-A1 | CYCLIC NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012040126-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012040127-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2009086192-A1 | BIODEGRADABLE PHOSPHATE PROTECTED NUCLEOTIDE DERIVATIVES AND THEIR USE AS CANCER, ANTI VIRAL AND ANTI PARASITIC AGENTS | ALIOS BIOPHARMA, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009086201-A1 | 2-5A ANALOGS AND THEIR USE AS ANTI-CANCER, ANTI-VIRAL AND ANTI- PARAS ITI C AGENTS | ALIOS BIOPHARMA, INC. (US) | 2009-07-09 | — | — | WO | disclosed |